Houston investment group names new leadership

movers & shakers

Goose Capital recently named its new managing director, president, and board chair. Photo courtesy

A Houston-based investment group has announced three new leadership changes to its organization to start of the new year.

Goose Capital Inc. named Chris Staffel as managing director, along with Jeff Smisek as the firm's president and Jay Collins as chair of the board of directors. The three appointments are effective as of January 1.

Smisek, former chairman, CEO, and president of United Continental Holdings Inc., has been a member investor with Goose but now assumes this leadership role. He serves as president of private investment company Flight Partners Capital, as well as on the board of directors for Finch Therapeutics Group Inc., Lantha Inc., and Molecular Match Inc.

"I look forward to leading Goose Capital as we help early stage companies and their founders develop their products, grow their companies, and create value," says Smisek in a news release.

Collins formerly lead Oceaneering International as CEO and president. He currently serves on the board of directors of the company as well as on the boards of Murphy Oil Company and Pason Systems Inc. Prior to becoming chair of the board of Goose Capital, Collins was its president.

A serial entrepreneur and investor in over 30 startups, Staffel joins Goose to lead day-to-day operations and drive new investment opportunities. She has been a founding member of three startup energy companies with an aggregate exit valuation of $1.38 billion, according to the release, as well as formerly leading Houston-based digital health company, Patients We Share, as COO. Her appointment to the firm follows former director Samantha Lewis's move to Mercury Fund.

"It is an honor to join the team at Goose Capital and work alongside experienced industry leaders," Staffel says in the release. "I look forward to leveraging my entrepreneurial experience to help the start-ups in which we invest, while strategically identifying early stage investment opportunities."

Goose Capital — previously known as The GOOSE Society of Texas — was founded 15 years ago and invests about $10 million per year in early-stage companies. Last summer, the organization rebranded with a new website representing a new phase for the investment group.

GOOSE Society of Texas has invested in a chemical sensor company from Austin. Pexels

Houston investor group leads $2.6 million Series A round for Austin-based chemical sensor startup

Money moves

A Houston-based investment group has announced funding for a startup out of Austin that has the potential to disrupt multiple industries with its chemical sensor device.

GOOSE Society of Texas, a group of investors that invest over $50 million into early stage startups, led the $2.6 million round for Lantha Inc. The startup plans to use the funds for finalizing its commercial products, strategic hires, and expand its intellectual property. The device Lantha has created can detect solid-state chemicals, which can be used in a myriad of industries from pharmaceuticals and oil and gas to water and defense.

Jeff Smisek, former United Airlines CEO and founder of investment firm Flight Partners Management LLC, was the GOOSE investor to lead the deal. According to a news release, he will join Lantha's board of directors.

"Lantha is a great example of the GOOSE Society's investment thesis — a company with proprietary and disruptive technology, low capital costs, large addressable markets, speedy product development and high margins which can benefit from the vast experience and contacts of the GOOSE Society's investors," Smisek says in the release. "We are proud to lead this financing and look forward to working closely with Lantha's management and world class scientists as they build a powerhouse in the field-based chemical analysis market."

Simon Humphrey, associate professor of chemistry at the University of Texas, invented the handheld device that is faster, cheaper, and easier to use than traditional tools. Humphrey serves as CTO for the company, and Robert Toker is the CEO and chairman of Lantha.

"We have world class scientists, who are the inventors of our technology, and a strong founding team, and we've attracted a great group of investors led by Jeff Smisek and the GOOSE Society in Houston as well as several prominent investors associated with the University of Texas at Austin," Toker says. "... Partnering with GOOSE has materially improved our chances of success."

The Lantha investment represents the first time GOOSE has funded technology coming out of UT.

"We are excited about expanding GOOSE's investment efforts to UT and look forward to future collaborations and deals," says Samantha Lewis, director at GOOSE. Several high-profile investors from the UT community invested in Lantha's Series A Preferred Stock alongside GOOSE investors.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings